Morgan Stanley Downgrades Infinity Pharmaceutical (INFI) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
William Blair Downgrades Infinity Pharmaceutical (INFI) to Market Perform
June 15, 2016 7:51 AM EDTWilliam Blair downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Outperform to Market Perform with a price target of $2.00 (from $20.00).
For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.
Shares of Infinity Pharmaceutical closed at $1.36 yesterday.
... MoreFBR Capital Downgrades Infinity Pharmaceutical (INFI) to Market Perform
June 14, 2016 3:43 PM EDTFBR Capital downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Outperform to Market Perform with a price target of $2.00 (from $15.00).
Analyst Christopher James commented, "We are downgrading our rating of Infinity Pharmaceuticals to Market Perform and lowering our price target to $2 from $15 following disappointing data from Infinity's Phase II DYNAMO study with duvelisib in patients with... More
Wedbush Upgrades Infinity Pharmaceutical (INFI) to Neutral
June 14, 2016 12:57 PM EDTWedbush upgraded Infinity Pharmaceutical (NASDAQ: INFI) from Underperform to Neutral with a price target of $1.25.
For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.
Shares of Infinity Pharmaceutical closed at $4.41 yesterday.
... MoreJPMorgan Downgrades Infinity Pharmaceutical (INFI) to Neutral
June 14, 2016 8:20 AM EDTJPMorgan downgraded Infinity Pharmaceutical (NASDAQ: INFI) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.
Shares of Infinity Pharmaceutical closed at $4.41 yesterday.
... MoreInfinity Pharma (INFI) Announces Duvelisib Phase 2 Met Primary Endpoint in r/r NHL; Will Undertake Restructuring
June 14, 2016 6:30 AM EDTInfinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that DYNAMO, a registration-focused Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with refractory indolent non-Hodgkin lymphoma (iNHL) met its primary endpoint of overall response rate. In the study, duvelisib demonstrated an overall response rate (ORR) of 46 percent, all of which were partial responses, among 129 patients with iNHL. The majority of reported side effects were reversible and clinically manageable.
"While the DYNAMO study met its primary endpoint, we... More
